
|Videos|October 20, 2016
High Cost Drug Launches and Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
4
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
5














































































































































































































